| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy.
|
Urology
|
2013
|
3.26
|
|
2
|
NCCN clinical practice guidelines in oncology: kidney cancer.
|
J Natl Compr Canc Netw
|
2009
|
2.40
|
|
3
|
Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
|
J Clin Oncol
|
2007
|
2.20
|
|
4
|
Medical treatment of advanced testicular cancer.
|
JAMA
|
2008
|
2.11
|
|
5
|
Chemotherapy for teratoma with malignant transformation.
|
J Clin Oncol
|
2003
|
2.06
|
|
6
|
TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis.
|
J Clin Oncol
|
2010
|
1.97
|
|
7
|
Histology and clinical outcomes in patients with bilateral testicular germ cell tumors: the Memorial Sloan Kettering Cancer Center experience 1950 to 2001.
|
J Urol
|
2003
|
1.95
|
|
8
|
Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
|
J Clin Oncol
|
2007
|
1.90
|
|
9
|
NCCN clinical practice guidelines in oncology: testicular cancer.
|
J Natl Compr Canc Netw
|
2009
|
1.86
|
|
10
|
Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
|
J Clin Oncol
|
2002
|
1.82
|
|
11
|
Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
|
J Clin Oncol
|
2007
|
1.74
|
|
12
|
Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy.
|
J Clin Oncol
|
2005
|
1.71
|
|
13
|
Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
|
J Clin Oncol
|
2005
|
1.68
|
|
14
|
Clinical outcome and predictors of survival in late relapse of germ cell tumor.
|
J Clin Oncol
|
2008
|
1.63
|
|
15
|
Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
|
J Urol
|
2005
|
1.62
|
|
16
|
Risks of the uncontrolled retroperitoneum.
|
Ann Surg Oncol
|
2003
|
1.61
|
|
17
|
Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
|
BJU Int
|
2007
|
1.51
|
|
18
|
Late relapse of testicular germ cell tumors.
|
Urol Oncol
|
2005
|
1.50
|
|
19
|
Retroperitoneal histologic findings of patients with elevated serum alpha-fetoprotein and pure seminoma at orchiectomy.
|
Urology
|
2011
|
1.45
|
|
20
|
Is there an increased incidence of contralateral testicular cancer in patients with intratesticular microlithiasis?
|
AJR Am J Roentgenol
|
2003
|
1.42
|
|
21
|
Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors.
|
J Clin Oncol
|
2005
|
1.41
|
|
22
|
Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.
|
J Clin Oncol
|
2006
|
1.36
|
|
23
|
Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
|
J Clin Oncol
|
2005
|
1.31
|
|
24
|
Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.
|
J Clin Oncol
|
2007
|
1.22
|
|
25
|
Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.
|
J Urol
|
2006
|
1.17
|
|
26
|
Association between sarcoidosis and testicular carcinoma: a diagnostic pitfall.
|
Sarcoidosis Vasc Diffuse Lung Dis
|
2007
|
1.17
|
|
27
|
Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors.
|
J Clin Oncol
|
2007
|
1.13
|
|
28
|
Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer.
|
Urology
|
2008
|
1.13
|
|
29
|
Testicular cancer.
|
J Natl Compr Canc Netw
|
2012
|
1.11
|
|
30
|
Adult and pediatric testicular teratoma.
|
Urol Clin North Am
|
2007
|
1.10
|
|
31
|
Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer.
|
J Urol
|
2007
|
1.09
|
|
32
|
Kidney cancer.
|
J Natl Compr Canc Netw
|
2011
|
1.06
|
|
33
|
The role of retroperitoneal lymph node dissection in the management of testicular cancer.
|
Urol Oncol
|
2004
|
1.03
|
|
34
|
Germ cell tumors of the testis.
|
Ann Surg Oncol
|
2005
|
1.02
|
|
35
|
Kidney cancer, version 2.2014.
|
J Natl Compr Canc Netw
|
2014
|
0.98
|
|
36
|
Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.
|
Cancer
|
2011
|
0.96
|
|
37
|
Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome.
|
Urology
|
2003
|
0.96
|
|
38
|
Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.
|
Cancer
|
2007
|
0.94
|
|
39
|
Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis.
|
J Urol
|
2003
|
0.94
|
|
40
|
Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma.
|
J Urol
|
2004
|
0.90
|
|
41
|
Environmental toxicology of testicular cancer.
|
Urol Oncol
|
2012
|
0.89
|
|
42
|
Retroperitoneal lymph node dissection: reassessment of modified templates.
|
BJU Int
|
2009
|
0.88
|
|
43
|
Rare de novo germline copy-number variation in testicular cancer.
|
Am J Hum Genet
|
2012
|
0.87
|
|
44
|
Management of post-chemotherapy extra-retroperitoneal residual masses.
|
World J Urol
|
2009
|
0.86
|
|
45
|
Testicular Cancer, Version 2.2015.
|
J Natl Compr Canc Netw
|
2015
|
0.86
|
|
46
|
Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer.
|
J Urol
|
2006
|
0.85
|
|
47
|
Evaluation of lymph node counts in primary retroperitoneal lymph node dissection.
|
Cancer
|
2010
|
0.84
|
|
48
|
Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older.
|
Cancer
|
2013
|
0.84
|
|
49
|
Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy.
|
J Clin Oncol
|
2004
|
0.84
|
|
50
|
Retroperitoneal lymph node dissection after chemotherapy.
|
BJU Int
|
2009
|
0.81
|
|
51
|
Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour.
|
BJU Int
|
2012
|
0.81
|
|
52
|
Contemporary lymph node counts during primary retroperitoneal lymph node dissection.
|
Urology
|
2010
|
0.81
|
|
53
|
Critical elements in fellowship training.
|
Urol Oncol
|
2009
|
0.81
|
|
54
|
The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer.
|
Urology
|
2010
|
0.81
|
|
55
|
The current status of laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ-cell tumors.
|
Nat Clin Pract Urol
|
2005
|
0.80
|
|
56
|
Salvage chemotherapy for patients with advanced pure seminoma.
|
J Clin Oncol
|
2002
|
0.80
|
|
57
|
Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors.
|
Invest New Drugs
|
2007
|
0.80
|
|
58
|
Management of recurrence and follow-up strategies for patients with seminoma and selected high-risk groups.
|
Urol Clin North Am
|
2003
|
0.79
|
|
59
|
Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site.
|
Urology
|
2012
|
0.79
|
|
60
|
Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.
|
Urology
|
2012
|
0.79
|
|
61
|
Retroperitoneal lymph node dissection (RPLND).
|
Gynecol Oncol
|
2008
|
0.78
|
|
62
|
Surgery for retroperitoneal relapse in the setting of a prior retroperitoneal lymph node dissection for germ cell tumor.
|
Indian J Urol
|
2010
|
0.78
|
|
63
|
Recommendations of follow-up after treatment of germ cell tumors.
|
Semin Oncol
|
2003
|
0.78
|
|
64
|
Cervical metastasis of germ cell tumors: evaluation, management, complications, and outcomes.
|
Laryngoscope
|
2012
|
0.78
|
|
65
|
Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors.
|
Invest New Drugs
|
2004
|
0.77
|
|
66
|
Management of patients with low-stage nonseminomatous germ cell testicular cancer.
|
Curr Treat Options Oncol
|
2005
|
0.77
|
|
67
|
Impact of unnecessary exploratory laparotomy on the treatment of patients with metastatic germ cell tumor.
|
J Urol
|
2004
|
0.77
|
|
68
|
Postchemotherapy surgery for germ cell tumors of the testis.
|
Curr Opin Oncol
|
2011
|
0.77
|
|
69
|
Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors.
|
J Urol
|
2004
|
0.77
|
|
70
|
Paracolic recurrence: the importance of wide excision of the spermatic cord at retroperitoneal lymph node dissection.
|
J Urol
|
2002
|
0.77
|
|
71
|
Testicular cancer. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2006
|
0.76
|
|
72
|
The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
|
Cancer
|
2008
|
0.76
|
|
73
|
The role of lymphadenectomy for testicular cancer: indications, controversies, and complications.
|
Urol Clin North Am
|
2011
|
0.76
|
|
74
|
Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection.
|
Urology
|
2011
|
0.75
|
|
75
|
Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update.
|
Urology
|
2011
|
0.75
|
|
76
|
Stage I testicular cancer management and necessity for surgical expertise.
|
J Clin Oncol
|
2008
|
0.75
|
|
77
|
Editorial comment.
|
Urology
|
2012
|
0.75
|
|
78
|
Editorial: predicting necrosis after chemotherapy for advanced nonseminomatous germ cell tumor-surrogate end points, decreasing morbidity and patient outcome.
|
J Urol
|
2004
|
0.75
|
|
79
|
Reply: To PMID 24094653.
|
Urology
|
2013
|
0.75
|
|
80
|
Kidney cancer. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2006
|
0.75
|
|
81
|
The management of subcentimeter residual mass in NSGCT: pcRPLND vs. observation.
|
Urol Oncol
|
2011
|
0.75
|
|
82
|
Prolonged survival following salvage surgery for chemorefractory ovarian immature teratoma: a case report and review of the literature.
|
Gynecol Oncol
|
2005
|
0.75
|
|
83
|
Testicular cancer. Clinical practice guidelines.
|
J Natl Compr Canc Netw
|
2005
|
0.75
|
|
84
|
Kidney cancer. Clinical practice guidelines.
|
J Natl Compr Canc Netw
|
2005
|
0.75
|
|
85
|
Introduction: International consultation on urologic diseases: testicular cancer: Societe Internationale d'Urologie/International Consultation on Urologic Diseases Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.
|
Urology
|
2011
|
0.75
|
|
86
|
Challenges in testicular cancer management.
|
World J Urol
|
2009
|
0.75
|
|
87
|
Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma.
|
Urology
|
2003
|
0.75
|